RxDoctor Payments Data

James Hoff, MD

Interventional Cardiology · Joplin, MONPI 1043253693

Payments from drug & device makers

$1,720in general payments, 2019–2025

Across 62 payments — averaging $27.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$240
  • Heartflow, Inc.$193
  • AstraZeneca$179
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$138
  • Abbott$131
  • Alnylam Pharmaceuticals Inc.$110
  • plus $730 from 18 others

What the payments were for

  • Food & beverage$1,720100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,720 in reported general payments places this provider in the 10th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$172,199
Medicare patients
1,495
Services billed
3,524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan130$143,849
EliquisApixaban80$86,194
Repatha SureclickEvolocumab100$81,814
FarxigaDapagliflozin Propanediol25$24,974
Repatha SyringeEvolocumab23$12,246
Praluent PenAlirocumab11$7,411
Ranolazine ErRanolazine58$6,365
Rosuvastatin Calcium359$5,849
Metoprolol Succinate283$4,585
Bumetanide98$3,988
Atorvastatin Calcium217$2,880
Prasugrel Hcl35$1,829
Carvedilol175$1,787
Amlodipine Besylate224$1,525
Irbesartan63$1,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$83$143,849130 claims
PfizerEliquis$68$86,19480 claims
AstraZenecaFarxiga$179$24,97425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 182 interventional cardiology providers in Missouri.

Other interventional cardiology in Joplin

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →